Loading company…
Mineralys Therapeutics develops treatments for hypertension and other diseases linked to elevated aldosterone.
Founded in 2020 and based in Pennsylvania, US, Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for diseases driven by elevated aldosterone. Its lead product, Lorundrostat, is being developed for aldosterone-dependent hypertension. In February 2024, the company raised USD 120 million in PIPE funding co-led by TCG Crossover Management and RA Capital Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in